Biomarkers in previous histologically negative prostate biopsies can be helpful in repeat biopsy decision‐making processes
Abstract To evaluate whether the addition of biomarkers to traditional clinicopathological parameters may help to increase the accurate prediction of prostate re‐biopsy outcome. A training cohort with 98 patients and a validation cohort with 72 patients were retrospectively recruited into our study....
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-10-01
|
Series: | Cancer Medicine |
Subjects: | |
Online Access: | https://doi.org/10.1002/cam4.3419 |
id |
doaj-ff172d4541214dc2b5e83ddfb71d9da7 |
---|---|
record_format |
Article |
spelling |
doaj-ff172d4541214dc2b5e83ddfb71d9da72020-11-25T03:41:37ZengWileyCancer Medicine2045-76342020-10-019207524753610.1002/cam4.3419Biomarkers in previous histologically negative prostate biopsies can be helpful in repeat biopsy decision‐making processesXingbo Long0Longxiang Wu1Xiting Zeng2Zhijian Wu3Xiheng Hu4Huichuan Jiang5Zhengtong Lv6Changzhao Yang7Yi Cai8Keda Yang9Yuan Li10Department of Urology Beijing HospitalNational Center of Gerontology Beijing ChinaDepartment of Urology Xiangya HospitalCentral South University Changsha ChinaDepartment of Ophthalmology The Affiliated XiangTan Hospital XiangYa Medical College CSU (XiangTan Central Hospital) XiangTan Hunan ChinaDepartment of Urology Chenzhou No.1 People’s Hospital ChengZhou Hunan ChinaDepartment of Urology Xiangya HospitalCentral South University Changsha ChinaDepartment of Urology Xiangya HospitalCentral South University Changsha ChinaDepartment of Urology Xiangya HospitalCentral South University Changsha ChinaDepartment of Urology Xiangya HospitalCentral South University Changsha ChinaDepartment of Urology Xiangya HospitalCentral South University Changsha ChinaDepartment of Pathology Xiangya HospitalCentral South University Changsha Hunan ChinaDepartment of Urology Xiangya HospitalCentral South University Changsha ChinaAbstract To evaluate whether the addition of biomarkers to traditional clinicopathological parameters may help to increase the accurate prediction of prostate re‐biopsy outcome. A training cohort with 98 patients and a validation cohort with 72 patients were retrospectively recruited into our study. Immunohistochemical analysis was used to evaluate the immunoreactivity of a group of biomarkers in the initial negative biopsy normal‐looking tissues of the training and validation cohorts. p‐STAT3, Mcm2, and/or MSR1 were selected out of 10 biomarkers to construct a biomarker index for predicting cancer and high‐grade prostate cancer (HGPCa) in the training cohort based on the stepwise logistic regression analysis; these biomarkers were then validated in the validation cohort. In the training cohort study, we found that the biomarker index was independently associated with the re‐biopsy outcomes of cancer and HGPCa. Moreover supplementing the biomarker index with traditional clinical‐pathological parameters can improve the area under the receiver operating characteristic curve of the model from 0.722 to 0.842 and from 0.735 to 0.842, respectively, for predicting cancer and HGPCa at re‐biopsy. In the decision‐making analysis, we found the model supplemented with the biomarker index can improve patients’ net benefit. The application of the model to clinical practice, at a 10% risk threshold, would reduce the number of biopsies by 34.7% while delaying the diagnosis of 7.8% cancers and would reduce the number of biopsies by 73.5% while delaying the diagnosis of 17.8% HGPCas. Taken together, supplementing the biomarker index with clinicopathological parameters may help urologists in re‐biopsy decision‐making processes.https://doi.org/10.1002/cam4.3419BiomarkerDecision‐making processField effectProstate cancerRepeat prostate biopsy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Xingbo Long Longxiang Wu Xiting Zeng Zhijian Wu Xiheng Hu Huichuan Jiang Zhengtong Lv Changzhao Yang Yi Cai Keda Yang Yuan Li |
spellingShingle |
Xingbo Long Longxiang Wu Xiting Zeng Zhijian Wu Xiheng Hu Huichuan Jiang Zhengtong Lv Changzhao Yang Yi Cai Keda Yang Yuan Li Biomarkers in previous histologically negative prostate biopsies can be helpful in repeat biopsy decision‐making processes Cancer Medicine Biomarker Decision‐making process Field effect Prostate cancer Repeat prostate biopsy |
author_facet |
Xingbo Long Longxiang Wu Xiting Zeng Zhijian Wu Xiheng Hu Huichuan Jiang Zhengtong Lv Changzhao Yang Yi Cai Keda Yang Yuan Li |
author_sort |
Xingbo Long |
title |
Biomarkers in previous histologically negative prostate biopsies can be helpful in repeat biopsy decision‐making processes |
title_short |
Biomarkers in previous histologically negative prostate biopsies can be helpful in repeat biopsy decision‐making processes |
title_full |
Biomarkers in previous histologically negative prostate biopsies can be helpful in repeat biopsy decision‐making processes |
title_fullStr |
Biomarkers in previous histologically negative prostate biopsies can be helpful in repeat biopsy decision‐making processes |
title_full_unstemmed |
Biomarkers in previous histologically negative prostate biopsies can be helpful in repeat biopsy decision‐making processes |
title_sort |
biomarkers in previous histologically negative prostate biopsies can be helpful in repeat biopsy decision‐making processes |
publisher |
Wiley |
series |
Cancer Medicine |
issn |
2045-7634 |
publishDate |
2020-10-01 |
description |
Abstract To evaluate whether the addition of biomarkers to traditional clinicopathological parameters may help to increase the accurate prediction of prostate re‐biopsy outcome. A training cohort with 98 patients and a validation cohort with 72 patients were retrospectively recruited into our study. Immunohistochemical analysis was used to evaluate the immunoreactivity of a group of biomarkers in the initial negative biopsy normal‐looking tissues of the training and validation cohorts. p‐STAT3, Mcm2, and/or MSR1 were selected out of 10 biomarkers to construct a biomarker index for predicting cancer and high‐grade prostate cancer (HGPCa) in the training cohort based on the stepwise logistic regression analysis; these biomarkers were then validated in the validation cohort. In the training cohort study, we found that the biomarker index was independently associated with the re‐biopsy outcomes of cancer and HGPCa. Moreover supplementing the biomarker index with traditional clinical‐pathological parameters can improve the area under the receiver operating characteristic curve of the model from 0.722 to 0.842 and from 0.735 to 0.842, respectively, for predicting cancer and HGPCa at re‐biopsy. In the decision‐making analysis, we found the model supplemented with the biomarker index can improve patients’ net benefit. The application of the model to clinical practice, at a 10% risk threshold, would reduce the number of biopsies by 34.7% while delaying the diagnosis of 7.8% cancers and would reduce the number of biopsies by 73.5% while delaying the diagnosis of 17.8% HGPCas. Taken together, supplementing the biomarker index with clinicopathological parameters may help urologists in re‐biopsy decision‐making processes. |
topic |
Biomarker Decision‐making process Field effect Prostate cancer Repeat prostate biopsy |
url |
https://doi.org/10.1002/cam4.3419 |
work_keys_str_mv |
AT xingbolong biomarkersinprevioushistologicallynegativeprostatebiopsiescanbehelpfulinrepeatbiopsydecisionmakingprocesses AT longxiangwu biomarkersinprevioushistologicallynegativeprostatebiopsiescanbehelpfulinrepeatbiopsydecisionmakingprocesses AT xitingzeng biomarkersinprevioushistologicallynegativeprostatebiopsiescanbehelpfulinrepeatbiopsydecisionmakingprocesses AT zhijianwu biomarkersinprevioushistologicallynegativeprostatebiopsiescanbehelpfulinrepeatbiopsydecisionmakingprocesses AT xihenghu biomarkersinprevioushistologicallynegativeprostatebiopsiescanbehelpfulinrepeatbiopsydecisionmakingprocesses AT huichuanjiang biomarkersinprevioushistologicallynegativeprostatebiopsiescanbehelpfulinrepeatbiopsydecisionmakingprocesses AT zhengtonglv biomarkersinprevioushistologicallynegativeprostatebiopsiescanbehelpfulinrepeatbiopsydecisionmakingprocesses AT changzhaoyang biomarkersinprevioushistologicallynegativeprostatebiopsiescanbehelpfulinrepeatbiopsydecisionmakingprocesses AT yicai biomarkersinprevioushistologicallynegativeprostatebiopsiescanbehelpfulinrepeatbiopsydecisionmakingprocesses AT kedayang biomarkersinprevioushistologicallynegativeprostatebiopsiescanbehelpfulinrepeatbiopsydecisionmakingprocesses AT yuanli biomarkersinprevioushistologicallynegativeprostatebiopsiescanbehelpfulinrepeatbiopsydecisionmakingprocesses |
_version_ |
1724529250532327424 |